|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Adolor Corp., of Exton, Pa., and GlaxoSmithKline plc, of London, said enrollment in a Phase III trial to evaluate the oral drug Entereg (alvimopan) has been completed. Entereg is being developed to treat gastrointestinal events caused by opioids used for persistent noncancer pain. Enrollment of a Phase IIb study in cancer patients with persistent pain also has been completed. The companies said enrollment was completed earlier than expected, and they plan to file an NDA and MAA in mid-2007.
o Aldagen Inc., of Durham, N.C., said the FDA cleared an IND application to conduct a clinical trial using its Aldesort product to isolate a unique stem cell population for ...